/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
A slap on the wrist from the regulator hasn’t really helped restore investors’ faith in a company dogged by multiple governance and ethical issues.
Sun Pharmaceutical Industries Ltd, its owner Dilip Shanghvi and six board members are out of the doghouse. They’ve finally managed to shake off the regulatory overhang that’s haunted them for over two years now. In the second week of February, India’s fourth most valuable pharma company settled charges of poor governance standards and non-disclosure of related party transactions, among others, with the market regulator.
The media, which had been giving the pharma company a hard time all this while, was much kinder this time around, with mere mentions of the Securities and Exchange Board of India settlement orders. A cumulative …
Thinly traded listed entities have long served as breeding grounds for stock manipulation, hurting investors. The regulator, the NSE and BSE now want to fix things by focusing on efficient delisting.
The newly announced levy on UPI payments undermines the very foundation of using digital payments for stock market investing. Brokers are in a tizzy.
A Rs 10,440 crore share swap with listed Shalimar Paints could give the building materials startup a public market presence without a traditional IPO. But the novel route leaves investors grappling with dilution, valuation and governance concerns.
